Improving the Therapeutic Efficacy of Anti-Cancer Drugs through Nanotechnology
American Journal of Pharmaceutics · 2022-02-28 · 3 (1) · 16-31
DOI: 10.71465/ajph2163 ↗At a glance
Journal article in American Journal of Pharmaceutics, published online on 2022-02-28. Written by Dr. John Doe. The full text is freely available (open access, CC BY 4.0).
Abstract (original language)
Nanotechnology has emerged as a promising strategy to enhance the therapeutic efficacy of anti-cancer drugs. Traditional cancer treatments often face limitations such as poor bioavailability, toxicity, and resistance. Nanotechnology provides innovative solutions by utilizing nanoscale materials to improve the delivery, effectiveness, and targeting of anti-cancer drugs. This article explores the role of nanotechnology in improving drug bioavailability, targeting specific tumor sites, minimizing side effects, and overcoming resistance mechanisms. The application of nanocarriers, such as liposomes, dendrimers, and nanoparticles, offers new avenues in precision cancer therapy. Furthermore, it discusses the clinical challenges and future directions for integrating nanotechnology into cancer treatment.
Cite
APA
Doe, D. J. (2022). Improving the Therapeutic Efficacy of Anti-Cancer Drugs through Nanotechnology. American Journal of Pharmaceutics, 3(1), 16-31. https://doi.org/10.71465/ajph2163
Vancouver
Doe DJ. Improving the Therapeutic Efficacy of Anti-Cancer Drugs through Nanotechnology. American Journal of Pharmaceutics. 2022;3(1):16-31. doi:10.71465/ajph2163
BibTeX
@article{Doe2022,
author = {Doe, Dr. John},
title = {Improving the Therapeutic Efficacy of Anti-Cancer Drugs through Nanotechnology},
journal = {American Journal of Pharmaceutics},
year = {2022},
volume = {3},
number = {1},
pages = {16--31},
doi = {10.71465/ajph2163}
}
EUVIMED